Pennsylvania Convention Center

Diverse Range of Packaging Solutions Showcased at PAC Machinery’s Pack Expo East Exhibit

Retrieved on: 
Wednesday, January 31, 2024

SAN RAFAEL, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) --  PAC Machinery (PAC), a leader in packaging equipment and materials with one of the most comprehensive ranges of equipment, will capitalize on machine diversity with the exhibit of three packaging machines – all from different categories at the biennial Pack Expo East Show that brings cutting-edge packaging solutions to the East Coast.

Key Points: 
  • SAN RAFAEL, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) --  PAC Machinery (PAC), a leader in packaging equipment and materials with one of the most comprehensive ranges of equipment, will capitalize on machine diversity with the exhibit of three packaging machines – all from different categories at the biennial Pack Expo East Show that brings cutting-edge packaging solutions to the East Coast.
  • PACK EXPO East 2024, will be held March 18-20 at the Pennsylvania Convention Center, Philadelphia, PA.
  • PAC Machinery, a leader in the flexible packaging industry, will exhibit at #1427 with top-selling packaging solutions including Rollbag® R785 Automatic Bagger, the D545 AV Band Sealer and PVT Plus Vacuum Sealer – all machines that have been top-selling solutions for PAC Machinery in part due to the flexibility these solutions provide for a wide variety of industries.
  • PAC Machinery equipment experts will be at the booth to have discussions that help solve pain points and challenges in packaging operations and packaging projects.

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients

Retrieved on: 
Monday, November 13, 2023

Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100® diagnostic blood test benefitted patients with acute decompensated heart failure (ADHF). Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.

Key Points: 
  • Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023.
  • Data showed that on average 7 out of 10 ADHF patients are not being accurately diagnosed.
  • Clinical assessments of volume status and anemia were collected for all patients prior to BVA measurement at hospital admission and post-discharge.
  • Patients in the BVA-guided arm received treatment informed by the BVA test results, in the blinded arm volume was only assessed using clinical tools and biomarkers absent the BVA results.

ASPC and PACH to Host Dinner Program During #AHA23 to Discuss Issues Surrounding Patient Access to Cardiovascular Medications

Retrieved on: 
Wednesday, November 8, 2023

The dinner coincides with the American Heart Association's annual scientific sessions conference hosted at the Pennsylvania Convention Center from November 11-13.

Key Points: 
  • The dinner coincides with the American Heart Association's annual scientific sessions conference hosted at the Pennsylvania Convention Center from November 11-13.
  • We hope this conversation shines a light on some of the access challenges physicians face every day in the clinic.
  • The dinner program is complimentary to attend, but guests must pre-register online: https://www.eventbrite.com/e/forecasting-patient-access-innovation-forum...
    "We are excited to partner with ASPC to bring this meaningful conversation about patient access to the cardiology community," says PACH Executive Director Ryan Gough.
  • The ASPC is a non-profit membership-based association dedicated to educating health care professionals and patients about the prevention of cardiovascular diseases.

Nuevocor presents pre-clinical data at ESGCT and AHA meetings

Retrieved on: 
Tuesday, November 7, 2023

SINGAPORE, Nov. 7, 2023 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress, and the American Heart Association (AHA) Scientific Sessions 2023.

Key Points: 
  • SINGAPORE, Nov. 7, 2023 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress, and the American Heart Association (AHA) Scientific Sessions 2023.
  • The poster presentations showcase optimization efforts for Nuevocor's first-in-class lead programme using a mechanobiology-based approach to treat LMNA-associated dilated cardiomyopathy.
  • At the ESGCT Congress on 24 – 27 October, 2023 in Brussels, Belgium, Nuevocor co-founder and Chief Executive Officer, Dr. Yann Chong Tan, presented a poster (P613) entitled "An AAV gene therapy for LMNA dilated cardiomyopathy via disruption of the LINC complex."
  • For more information on the meetings, please visit the respective conference websites.

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

Retrieved on: 
Friday, November 3, 2023

Ardelyx’s presence at Kidney Week 2023 will honor the memory of Derek Forfang, Chair of the Ardelyx Patient Advisory Council and a passionate advocate for patients with kidney disease.

Key Points: 
  • Ardelyx’s presence at Kidney Week 2023 will honor the memory of Derek Forfang, Chair of the Ardelyx Patient Advisory Council and a passionate advocate for patients with kidney disease.
  • XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.
  • Additionally, Ardelyx is hosting an XPHOZAH Exhibitor Spotlight at ASN Kidney Week 2003.
  • Director of Home and Peritoneal Dialysis Programs, Boise Kidney & Hypertension Institute, and by David Spiegel, MD, Vice President of Nephrology at Ardelyx.

Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023

Retrieved on: 
Thursday, November 2, 2023

THE WOODLANDS, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that five data presentations related to INPEFA® (sotagliflozin) will be delivered during the American Heart Association Scientific Sessions 2023, November 11-13, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.

Key Points: 
  • “Our significant upcoming presence at the American Heart Association Scientific Sessions 2023 reflects the dedication of investigators to expanding the scientific evidence available to clinicians and payers as they make decisions around how to best utilize available treatment options in patients,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.
  • “We look forward to engaging with attendees and continuing to demonstrate both the clinical and economic value of INPEFA.”
    Details of the presentations are as follows:
    Sotagliflozin is associated with early clinical benefit for heart failure and atherosclerotic events – an oral presentation, Sunday, November 12, 2:10 - 2:15 p.m.
  • ET, Board #2122, presented by Slaven Sikirica, M.Sc., Lexicon Pharmaceuticals
    Sotagliflozin, a dual SGLT 1 and 2 Inhibitor, has high membrane affinity and hydrocarbon core location compared with empagliflozin – an ePoster, Sunday, November 12, 3:30 - 3:45 p.m.
  • ET, Board #2222, presented by Preston Mason, M.D., Brigham and Women’s Hospital, Boston, MA
    Relationship between left ventricular ejection fraction and ICD-10 codes among patients hospitalized with heart failure – a poster presentation, Saturday, November 11, 3:00 - 4:15 p.m.

New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting

Retrieved on: 
Monday, October 30, 2023

THE WOODLANDS, Texas, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to sotagliflozin, as well as data from a Lexicon-supported scientific study of patients hospitalized with heart failure who also had chronic kidney disease (CKD), will be presented during the American Society of Nephrology (ASN) Kidney Week Annual Meeting, November 2-5, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to sotagliflozin, as well as data from a Lexicon-supported scientific study of patients hospitalized with heart failure who also had chronic kidney disease (CKD), will be presented during the American Society of Nephrology (ASN) Kidney Week Annual Meeting, November 2-5, 2023, at the Pennsylvania Convention Center in Philadelphia, PA.
  • Details of the presentations are as follows:
    Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease [TH-PO1144] – Late-Breaking Clinical Trial poster presentation, Thursday, November 2, 10:00 a.m. – 12:00 p.m.
  • ET, Exhibit Hall, Pennsylvania Convention Center, presented by Vikas Sridhar, M.D., University of Toronto
    Sotagliflozin and Kidney and Cardiorenal Outcomes in SCORED [FR-OR45] – an oral presentation, Friday, November 3, 5:06 - 5:15 p.m.
  • ET, Exhibit Hall, Pennsylvania Convention Center, presented by Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer
    “Across the various data presented, we seek to address the challenges and complications of diabetes and chronic kidney disease,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.

Bitterroot Bio to Present Preclinical Research at American Heart Association Conference

Retrieved on: 
Monday, October 30, 2023

PALO ALTO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA.

Key Points: 
  • PALO ALTO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA.
  • The abstract, titled "Blockade of CD47 Using a Novel Anti-CD47 Molecule, BRB-002, Attenuates Atherosclerosis in an ApoE Mouse Model," has been scheduled for a moderated oral presentation at 9:30 AM ET on Saturday, November 11th, 2023.
  • Dr. Craig Basson, Chief Medical Officer at Bitterroot Bio, commented on the presentation, saying, "We are honored to have the opportunity to present our research at the American Heart Association conference.
  • Our team at Bitterroot Bio is dedicated to advancing cardiovascular science, and we believe that BRB-002 has potential to improve the lives of many patients with atherosclerotic cardiovascular disease.

Diality to Unveil Moda-flx Hemodialysis System, Poster Data at ASN Kidney Week 2023

Retrieved on: 
Wednesday, November 1, 2023

Diality Inc. today announced that it will introduce its Moda-flx Hemodialysis System™ at ASN Kidney Week 2023, Nov. 1-5 at the Pennsylvania Convention Center in Philadelphia.

Key Points: 
  • Diality Inc. today announced that it will introduce its Moda-flx Hemodialysis System™ at ASN Kidney Week 2023, Nov. 1-5 at the Pennsylvania Convention Center in Philadelphia.
  • The technology will also be the subject of a poster session titled “ Blood Flowrate Accuracy with Diality Hemodialysis System ” [SA-P0618] to be presented from 10 a.m. to noon on Saturday, Nov. 4 in the exhibit hall.
  • Moda-flx is a patient-inspired hemodialysis system designed to empower healthcare professionals to choose what is best for patients, as well as their clinical practice.
  • “We believe it will represent a new paradigm in the treatment of kidney disease, and we’re excited to introduce it to the kidney care community at Kidney Week.”
    To view and learn more about the system, please visit Diality at ASN Kidney Week booth #2011.

DaVita Unveils New Research to Drive Health Equity and Improve Care Quality during Annual American Society of Nephrology Meeting

Retrieved on: 
Thursday, November 2, 2023

DENVER and PHILADELPHIA, Nov. 2, 2023 /PRNewswire/ -- DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is presenting the findings of five new research projects at the American Society of Nephrology (ASN)'s annual "Kidney Week," which is currently underway in Philadelphia. The studies are focused on driving health equity and reducing hospitalizations, among other outcomes.

Key Points: 
  • DENVER and PHILADELPHIA, Nov. 2, 2023 /PRNewswire/ -- DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita Inc., is presenting the findings of five new research projects at the American Society of Nephrology (ASN)'s annual "Kidney Week," which is currently underway in Philadelphia.
  • The studies are focused on driving health equity and reducing hospitalizations, among other outcomes.
  • To learn more about the CKD-RDN please click here , or stop by booth #1004 to meet with DCR representatives.
  • DaVita will share updates throughout the meeting on X (formerly Twitter) on @DaVitaDoc and @DaVitaResearch, and will join the online conversation using #KidneyWk.